ARSI Plus ADT Shows Survival Trend in Asian Metastatic Hormone-Sensitive Prostate Cancer
ARSI plus ADT showed a trend toward improved survival in Asian patients with metastatic hormone-sensitive prostate cancer, but results were not statistically significant. Prospective studies are needed to validate these findings.
An exploratory pooled analysis found that androgen receptor signaling inhibitors (ARSI) combined with androgen deprivation therapy (ADT) produced a trend toward improved overall survival in Asian patients with metastatic hormone-sensitive prostate cancer (mHSPC), though the results did not reach statistical significance. The analysis, published in Cancer Reports, reconstructed individual patient data from published Kaplan-Meier curves from the TITAN Asian subpopulation analysis, the TITAN Japanese subpopulation, and the LATITUDE Japanese subpopulation.
A total of 291 reconstructed individual patient data were analyzed, including 146 patients receiving ARSI plus ADT and 145 receiving placebo plus ADT. In the overall Asian cohort, the 3-year overall survival was 85.2% with ARSI plus ADT versus 77.6% with placebo plus ADT, representing a 32% reduction in the risk of death (HR = 0.68, 95% CI 0.44-1.03, p = 0.07). In the Japanese subpopulation, 3-year overall survival was 77.4% versus 72.4%, with a 45% reduction in death risk (HR = 0.55, 95% CI 0.29-1.04, p = 0.07). Neither analysis reached statistical significance.
The study noted that ARSI combined with ADT has demonstrated significant survival benefits in mHSPC in several clinical trials, but data specifically in Asian patients remain limited, with individual subgroup analyses showing trends that did not reach statistical significance. This exploratory analysis observed a trend toward improved survival with ARSI plus ADT in Asian patients with mHSPC that did not achieve statistical significance. Prospective studies are needed to validate these findings.